Platelet receptors as therapeutic targets: Past, present and future
- PMID: 28597906
- DOI: 10.1160/TH16-12-0911
Platelet receptors as therapeutic targets: Past, present and future
Abstract
Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ibα, and directed against GPVI, GPIIb/IIIa (integrin αIIbβ3), the thrombin receptor PAR-1, and the ADP receptor P2Y12. The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.
Keywords: Antiplatelet agents; GP IIb/IIIa; GP Ibα; GP VI; PAR-1.
Similar articles
-
Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.Thromb Haemost. 2007 Mar;97(3):435-43. Thromb Haemost. 2007. PMID: 17334511
-
[Mechanisms of platelet activation and development of antiplatelet agents].Arch Mal Coeur Vaiss. 1996 Nov;89(11 Suppl):1501-6. Arch Mal Coeur Vaiss. 1996. PMID: 9092410 French.
-
Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.Cardiovasc Hematol Disord Drug Targets. 2006 Sep;6(3):191-207. doi: 10.2174/187152906778249536. Cardiovasc Hematol Disord Drug Targets. 2006. PMID: 17017902 Review.
-
Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.Circulation. 2007 May 1;115(17):2323-30. doi: 10.1161/CIRCULATIONAHA.107.691279. Epub 2007 Apr 16. Circulation. 2007. PMID: 17438148
-
Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents.Curr Vasc Pharmacol. 2004 Jan;2(1):23-32. doi: 10.2174/1570161043476456. Curr Vasc Pharmacol. 2004. PMID: 15320830 Review.
Cited by
-
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting.J Hematol Oncol. 2019 Mar 7;12(1):26. doi: 10.1186/s13045-019-0709-6. J Hematol Oncol. 2019. PMID: 30845955 Free PMC article. Review.
-
Synthesis and Biological Evaluation of Resveratrol Methoxy Derivatives.Molecules. 2023 Jul 20;28(14):5547. doi: 10.3390/molecules28145547. Molecules. 2023. PMID: 37513418 Free PMC article.
-
ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients.Dermatol Ther (Heidelb). 2019 Sep;9(3):579-587. doi: 10.1007/s13555-019-0314-1. Epub 2019 Jul 11. Dermatol Ther (Heidelb). 2019. PMID: 31297711 Free PMC article.
-
Ethaninidothioic acid (R5421) is not a selective inhibitor of platelet phospholipid scramblase activity.Br J Pharmacol. 2020 Sep;177(17):4007-4020. doi: 10.1111/bph.15152. Epub 2020 Jun 30. Br J Pharmacol. 2020. PMID: 32496597 Free PMC article.
-
Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics.Pharmaceuticals (Basel). 2022 Sep 3;15(9):1101. doi: 10.3390/ph15091101. Pharmaceuticals (Basel). 2022. PMID: 36145322 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
